|
Aug 14
|
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
|
|
May 15
|
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Apr 2
|
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
|
|
Mar 27
|
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
|
|
Feb 21
|
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
|
|
Feb 15
|
Vaccinex, Inc. Announces Reverse Stock Split
|
|
Feb 12
|
Steven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Inc
|
|
Dec 4
|
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
|